Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2017—Roche announced the expanded use of the Ventana PD-L1 (SP142) Assay in non-small cell lung cancer and metastatic urothelial carcinoma in CE markets in which the Roche cancer immunotherapy medicine Tecentriq is approved.
November 2017—IntegraGen announced the CE-IVD marking and commercial launch of its miRpredX 31-3p test kit in the European Union.
November 2017—Blood Systems Research Institute announced a collaboration with Hologic to more precisely and efficiently measure the human immunodeficiency virus latent reservoir in clinical samples using Hologic’s Panther system.
November 2017—Royal Philips announced that two pathology laboratories in Austria have made the transition to a fully digital workflow. The Pathology Institute in Hall and the Pathology Institute at Tirol Kliniken Innsbruck have fully digitized their diagnostic process with Philips IntelliSite Pathology Solution, a whole slide imaging system for primary diagnosis.
November 2017—Vector Laboratories introduced the VectaFluor Duet kit, offering ready-to-use immunofluorescence double labeling. This kit is ideal for use on a range of frozen and formalin-fixed, paraffin-embedded tissue samples, combining primary and secondary antibodies to streamline workflow.
November 2017—Tetracore announced that its T-Cor 8 portable real-time PCR thermocycler has achieved CE-IVD status. The T-Cor 8, and its proprietary software, is a point-of-care diagnostic system that enables real-time molecular testing in hospitals, clinics, physician offices, and field applications.
November 2017—The Clinical and Laboratory Standards Institute has published “Developing and Managing a Medical Laboratory (Test) Utilization Program (GP49),” which provides guidance on the process for developing and effectively maintaining a test utilization or laboratory stewardship committee.
November 2017—Beckman Coulter Life Sciences has introduced DuraClone RE antibody panels for the detection of rare, abnormal events in blood disorders. The panels provide tools to study low frequency populations of abnormal CD5+ B cells (RE CLB), abnormal plasma cells (RE PC), or abnormal B progenitor cells (RE ALB).
November 2017—Mologic (Thurleigh, U.K.) received CE marking for its BVPro, a 15-minute point-of-care diagnostic that detects sialidase enzyme activity from a vaginal swab sample.
November 2017—iBio has partnered with TheoremDx to develop proteins for rapid diagnostic testing products. The collaboration will leverage the TheoremDx point-of-care diagnostic system and the protein development and manufacturing capabilities
